Whitney Gladney

Whitney Gladney

Auto-generated profile, based on publicly available information

Whitney Gladney

Kite, a Gilead Company, Santa Monica, California

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
AGAnna Maria Giudice
Anna Maria Giudice
SMStephanie Matlaga
Stephanie Matlaga
SRSydney L. Roth
Sydney L. Roth
WGWhitney Gladney
Whitney Gladney
DGDavid Groff
David Groff
KBKristopher R. Bosse
Kristopher R. Bosse
Purpose: We previously identified glypican 2 (GPC2) as a cell-surface MYCN-regulated neuroblastoma oncoprotein and developed a D3-GPC2 antibody that specifically binds a conformational, tumor-specific epitope conserved between mouse and human. Experimental Design: In this study, we sought to further validate GPC2 as an immunotherapeutic target and develop Investigational New Drug application–enabling data to support the clinical translation of D3-GPC2 chimeric antigen receptor (CAR) T cells. Results: Immunohistochemistry validated that GPC2 is widely expressed on human neuroblastomas, and flow cytometry showed high levels of cell-surface GPC2 on neuroblastoma cellular models. Second-generation D3-GPC2 CAR T cells with either a 4-1BB or CD28 co-stimulatory domain were selectively activated and induced potent neuroblastoma cell cytotoxicity in several complementary in vitro co-incubation assays. Conversely, no measurable cytotoxicity or D3-GPC2 CAR T-cell activation was observed in co-incubation studies with nine primary human normal tissue cell lines. Moreover, GPC2 CAR T cells induced significant regression of GPC2-expressing neuroblastoma xenografts. No GPC2 CAR-related toxicities were noted, including in comprehensive mouse necropsies performed after GPC2 CAR T-cell administration. Finally, to explore the potential broader clinical impact of GPC2 CAR T cells, we showed that they are also potently cytotoxic to preclinical models of GPC2-expressing small cell lung cancers. Conclusions: These data validate GPC2 as a bona fide CAR T-cell target in neuroblastoma and other cancers. The safety and preliminary efficacy of GPC2 CAR T cells are being tested in a first-in-human phase I clinical trial for children with relapsed/refractory neuroblastoma (NCT05650749).

15 December 2025
Verified
Other
Open access
AGAnna Maria Giudice
Anna Maria Giudice
SMStephanie Matlaga
Stephanie Matlaga
SRSydney L. Roth
Sydney L. Roth
WGWhitney Gladney
Whitney Gladney
DGDavid Groff
David Groff
KBKristopher R. Bosse
Kristopher R. Bosse
GPC2 on SCLC cells activate D3-GPC2 CAR T cells.

15 December 2025
Verified
Other
Open access
AGAnna Maria Giudice
Anna Maria Giudice
SMStephanie Matlaga
Stephanie Matlaga
SRSydney L. Roth
Sydney L. Roth
WGWhitney Gladney
Whitney Gladney
DGDavid Groff
David Groff
KBKristopher R. Bosse
Kristopher R. Bosse
Selective neuroblastoma cell cytotoxicity of D3-GPC2 CAR-BBz T cells generated from a second T cell donor.

15 December 2025
Verified
Other
Open access
AGAnna Maria Giudice
Anna Maria Giudice
SMStephanie Matlaga
Stephanie Matlaga
SRSydney L. Roth
Sydney L. Roth
WGWhitney Gladney
Whitney Gladney
DGDavid Groff
David Groff
KBKristopher R. Bosse
Kristopher R. Bosse
D3-GPC2 CAR T cells protect mice from liver metastases in a SCLC H526 metastatic tumor model.

15 December 2025
Verified
Other
Open access
AGAnna Maria Giudice
Anna Maria Giudice
SMStephanie Matlaga
Stephanie Matlaga
SRSydney L. Roth
Sydney L. Roth
WGWhitney Gladney
Whitney Gladney
DGDavid Groff
David Groff
KBKristopher R. Bosse
Kristopher R. Bosse
Normal human cell lines used for D3-GPC2 CAR T cell in vitro toxicology assays.

15 December 2025
Verified
Other
Open access
AGAnna Maria Giudice
Anna Maria Giudice
SMStephanie Matlaga
Stephanie Matlaga
SRSydney L. Roth
Sydney L. Roth
WGWhitney Gladney
Whitney Gladney
DGDavid Groff
David Groff
KBKristopher R. Bosse
Kristopher R. Bosse
Purpose:We previously identified glypican 2 (GPC2) as a cell-surface MYCN-regulated neuroblastoma oncoprotein and developed a D3-GPC2 antibody that specifically binds a conformational, tumor-specific epitope conserved between mouse and human.Experimental Design:In this study, we sought to further validate GPC2 as an immunotherapeutic target and develop Investigational New Drug application–enabling data to support the clinical translation of D3-GPC2 chimeric antigen receptor (CAR) T cells.Results:Immunohistochemistry validated that GPC2 is widely expressed on human neuroblastomas, and flow cytometry showed high levels of cell-surface GPC2 on neuroblastoma cellular models. Second-generation D3-GPC2 CAR T cells with either a 4-1BB or CD28 co-stimulatory domain were selectively activated and induced potent neuroblastoma cell cytotoxicity in several complementary in vitro co-incubation assays. Conversely, no measurable cytotoxicity or D3-GPC2 CAR T-cell activation was observed in co-incubation studies with nine primary human normal tissue cell lines. Moreover, GPC2 CAR T cells induced significant regression of GPC2-expressing neuroblastoma xenografts. No GPC2 CAR-related toxicities were noted, including in comprehensive mouse necropsies performed after GPC2 CAR T-cell administration. Finally, to explore the potential broader clinical impact of GPC2 CAR T cells, we showed that they are also potently cytotoxic to preclinical models of GPC2-expressing small cell lung cancers.Conclusions:These data validate GPC2 as a bona fide CAR T-cell target in neuroblastoma and other cancers. The safety and preliminary efficacy of GPC2 CAR T cells are being tested in a first-in-human phase I clinical trial for children with relapsed/refractory neuroblastoma (NCT05650749).